Urologic pathology specialist Dr. Kirk Wojno is now the chief medical officer at OncoCell MDx, a privately held company that is developing noninvasive, blood-based molecular tests for prostate cancer.
Dr. Kirk Wojno.Most recently, Wojno was chief of pathology and laboratory services and director of clinical research at Comprehensive Urology in Royal Oak, MI. Previously, he was also head of urologic pathology at the University of Michigan.
OncoCell MDx, a subsidiary of Cell MDx, has patented technology from Harvard University that it believes will help show the aggressiveness of prostate cancer, among other purposes.
